A citation-based method for searching scientific literature

Natalia Yanguas-Casás, Lucía Pedrosa, Ismael Fernández-Miranda, Margarita Sánchez-Beato. Cancers (Basel) 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Molecular and cellular insights into T cell exhaustion.
E John Wherry, Makoto Kurachi. Nat Rev Immunol 2015
50

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
Yi Miao, L Jeffrey Medeiros, Zijun Y Xu-Monette, Jianyong Li, Ken H Young. Front Oncol 2019
25
50

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, Jenna M Sullivan, Bruce R Blazar, Vijay K Kuchroo, Ana C Anderson. J Exp Med 2010
50

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.
Matias Autio, Suvi-Katri Leivonen, Oscar Brück, Satu Mustjoki, Judit Mészáros Jørgensen, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Harald Holte, Teijo Pellinen, Sirpa Leppä. Haematologica 2021
39
50

Primary Pulmonary Diffuse Large B Cell Lymphoma Mimicking Metastasis: A Case Report and Literature Review.
Bailong Liu, Hui Liu, Liang Guo, Yunfei Ma, Meng Guan, Min Liu. Onco Targets Ther 2020
1
100

Aberrant Circulating Th17 Cells in Patients with B-Cell Non-Hodgkin's Lymphoma.
Ting Lu, Shuang Yu, Yan Liu, Congcong Yin, Jingjing Ye, Zhi Liu, Daoxin Ma, Chunyan Ji. PLoS One 2016
21
50

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Ziju Y Xu-Monette, Min Xiao, Qingyan Au, Raghav Padmanabhan, Bing Xu, Nicholas Hoe, Sandra Rodríguez-Perales, Raul Torres-Ruiz, Ganiraju C Manyam, Carlo Visco,[...]. Cancer Immunol Res 2019
62
50

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Kai Fu, Dennis D Weisenburger, William W L Choi, Kyle D Perry, Lynette M Smith, Xinlan Shi, Christine P Hans, Timothy C Greiner, Philip J Bierman, R Gregory Bociek,[...]. J Clin Oncol 2008
252
50

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Andrew Davies, Thomas E Cummin, Sharon Barrans, Tom Maishman, Christoph Mamot, Urban Novak, Josh Caddy, Louise Stanton, Shamim Kazmi-Stokes, Andrew McMillan,[...]. Lancet Oncol 2019
112
50

Immuno-Oncology: Emerging Targets and Combination Therapies.
Henry T Marshall, Mustafa B A Djamgoz. Front Oncol 2018
173
50

LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
Colm Keane, Soi C Law, Clare Gould, Simone Birch, Muhammed B Sabdia, Lilia Merida de Long, Gayathri Thillaiyampalam, Emad Abro, Joshua W Tobin, Xiaohong Tan,[...]. Blood Adv 2020
41
50

Inflammatory Cells in Diffuse Large B Cell Lymphoma.
Roberto Tamma, Girolamo Ranieri, Giuseppe Ingravallo, Tiziana Annese, Angela Oranger, Francesco Gaudio, Pellegrino Musto, Giorgina Specchia, Domenico Ribatti. J Clin Med 2020
11
50

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Zheng Zhou, Laurie H Sehn, Alfred W Rademaker, Leo I Gordon, Ann S Lacasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D Zelenetz, Gregory A Abel, Maria A Rodriguez,[...]. Blood 2014
513
50

Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.
Vinayaka Kotraiah, Timothy W Phares, Cecille D Browne, James Pannucci, Marc Mansour, Amy R Noe, Kenneth D Tucker, Jayne M Christen, Charles Reed, Alecia MacKay,[...]. Front Immunol 2020
11
50

Immune-Checkpoint Inhibitors in B-Cell Lymphoma.
Marc Armengol, Juliana Carvalho Santos, Miranda Fernández-Serrano, Núria Profitós-Pelejà, Marcelo Lima Ribeiro, Gaël Roué. Cancers (Basel) 2021
12
50

PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Marion Four, Valère Cacheux, Ariane Tempier, Dolorès Platero, Michel Fabbro, Grégory Marin, Nicolas Leventoux, Valérie Rigau, Valérie Costes-Martineau, Vanessa Szablewski. Hematol Oncol 2017
37
50

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, Philippe Armand, Emma C Scott, Ahmad Halwani, Martin Gutierrez, Michael M Millenson, Adam D Cohen, Stephen J Schuster, Daniel Lebovic,[...]. J Clin Oncol 2016
687
50

Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.
H Nishimura, Y Agata, A Kawasaki, M Sato, S Imamura, N Minato, H Yagita, T Nakano, T Honjo. Int Immunol 1996
179
50

Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Luisa Barrueto, Francheska Caminero, Lindsay Cash, Courtney Makris, Purushottam Lamichhane, Rahul R Deshmukh. Transl Oncol 2020
103
50

LAG3 and its emerging role in cancer immunotherapy.
Miao Wang, Qi Du, Jiangtao Jin, Yuhan Wei, Yuting Lu, Qin Li. Clin Transl Med 2021
17
50

Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion.
Alessandro Ascione, Claudia Arenaccio, Alessandra Mallano, Michela Flego, Mara Gellini, Mauro Andreotti, Craig Fenwick, Giuseppe Pantaleo, Stefano Vella, Maurizio Federico. BMC Biotechnol 2019
8
50

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, Yvonne Y Li, Grit S Herter-Sprie, Kevin A Buczkowski, William G Richards, Leena Gandhi, Amanda J Redig, Scott J Rodig, Hajime Asahina,[...]. Nat Commun 2016
873
50

Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma.
Weijie Zhong, Xin Xu, Zhigang Zhu, Li Yang, Hong Du, Zhongjun Xia, Zhaohu Yuan, Huabao Xiong, Qinghua Du, Yaming Wei,[...]. Int J Oncol 2018
17
50

Association Between Simian Virus 40 and Human Tumors.
John Charles Rotondo, Elisa Mazzoni, Ilaria Bononi, Mauro Tognon, Fernanda Martini. Front Oncol 2019
37
50

Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Elisa Ruffo, Richard C Wu, Tullia C Bruno, Creg J Workman, Dario A A Vignali. Semin Immunol 2019
102
50

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine.
Niraj Lodhi, Moe Tun, Poonam Nagpal, Arati A Inamdar, Nehad M Ayoub, Noor Siyam, Lucia Oton-Gonzalez, Angela Gerona, Dainelle Morris, Rana Sandhu,[...]. Oncotarget 2020
8
50

Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models.
Huizhong Xiong, Stephanie Mittman, Ryan Rodriguez, Patricia Pacheco-Sanchez, Marina Moskalenko, Yagai Yang, Justin Elstrott, Alex T Ritter, Sören Müller, Dorothee Nickles,[...]. Cancer Immunol Res 2019
25
50


Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Philippe Armand, Margaret A Shipp, Vincent Ribrag, Jean-Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen S Snyder, Alejandro D Ricart, Arun Balakumaran, Shelonitda Rose,[...]. J Clin Oncol 2016
463
50

New Insights into Diffuse Large B-Cell Lymphoma Pathobiology.
Antonio Giovanni Solimando, Tiziana Annese, Roberto Tamma, Giuseppe Ingravallo, Eugenio Maiorano, Angelo Vacca, Giorgina Specchia, Domenico Ribatti. Cancers (Basel) 2020
19
50

The immune microenvironment: a major player in human cancers.
W H Fridman, R Remark, J Goc, N A Giraldo, E Becht, Scott A Hammond, D Damotte, M-C Dieu-Nosjean, Catherine Sautès-Fridman. Int Arch Allergy Immunol 2014
45
50

5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.
Hang-Yu Chen, Wei-Long Zhang, Lei Zhang, Ping Yang, Fang Li, Ze-Ruo Yang, Jing Wang, Meng Pang, Yun Hong, Changjian Yan,[...]. Clin Epigenetics 2021
4
50

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, Monica V Goldberg, Jaishree Bankoti, Mark Selby, Christopher J Nirschl, Matthew L Bettini, David M Gravano, Peter Vogel, Chih Long Liu,[...]. Cancer Res 2012
966
50

Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Linh T Nguyen, Pamela S Ohashi. Nat Rev Immunol 2015
402
50

Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.
Alexandra Ioana Cioroianu, Patricia Irina Stinga, Liana Sticlaru, Mirela Daniela Cioplea, Luciana Nichita, Cristiana Popp, Florica Staniceanu. Anal Cell Pathol (Amst) 2019
30
50

Histone code and long non-coding RNAs (lncRNAs) aberrations in lung cancer: implications in the therapy response.
Abril Marcela Herrera-Solorio, Leonel Armas-López, Oscar Arrieta, Joaquín Zúñiga, Patricia Piña-Sánchez, Federico Ávila-Moreno. Clin Epigenetics 2017
20
50


Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma.
Hai Cheng, Zhiling Yan, Xue Wang, Jiang Cao, Wei Chen, Kunming Qi, Dian Zhou, Jieyun Xia, Na Qi, Zhenyu Li,[...]. Mol Cell Biochem 2019
19
50

Profiling and Molecular Mechanism Analysis of Long Non-Coding RNAs and mRNAs in Pulmonary Arterial Hypertension Rat Models.
Shiqiang Hou, Dandan Chen, Jie Liu, Shasha Chen, Xiaochun Zhang, Yuan Zhang, Mingfei Li, Wenzhi Pan, Daxin Zhou, Lihua Guan,[...]. Front Pharmacol 2021
5
50

Alteration of Epigenetic Regulation by Long Noncoding RNAs in Cancer.
Mariangela Morlando, Alessandro Fatica. Int J Mol Sci 2018
103
50


Long Noncoding RNA TRIM52-AS1 Sponges miR-514a-5p to Facilitate Hepatocellular Carcinoma Progression Through Increasing MRPS18A.
Chunhui Zhou, Zhen Chen, Changli Peng, Changyong Chen, Haiping Li. Cancer Biother Radiopharm 2021
13
50

LINC01094/miR-577 axis regulates the progression of ovarian cancer.
Jing Xu, Ping Zhang, Huajun Sun, Yang Liu. J Ovarian Res 2020
17
50

LINC00908 Promotes Diffuse Large B-Cell Lymphoma Development by Down-Regulating miR-671-5p.
Hong Zeng, Yongqiang Wei, Xiaolei Wei, Ru Feng. Cancer Manag Res 2021
3
50

The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer.
Marcell Lederer, Nadine Bley, Christian Schleifer, Stefan Hüttelmaier. Semin Cancer Biol 2014
146
50


Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications.
Vinay Singh Tanwar, Marpadga A Reddy, Rama Natarajan. Front Endocrinol (Lausanne) 2021
20
50

Downregulation of long non-coding RNA TRIM52-AS1 functions as a tumor suppressor in renal cell carcinoma.
Zan Liu, Hai-Yan Yan, Shun-Yao Xia, Cheng Zhang, You-Cheng Xiu. Mol Med Rep 2016
18
50

The Role of Long Non-coding RNAs in Human Imprinting Disorders: Prospective Therapeutic Targets.
Tingxuan Wang, Jianjian Li, Liuyi Yang, Manyin Wu, Qing Ma. Front Cell Dev Biol 2021
4
50

Regulation of Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer.
Ammad Ahmad Farooqi, Sawera Nayyab, Chiara Martinelli, Rossana Berardi, Hector Katifelis, Maria Gazouli, William C Cho. Front Oncol 2021
9
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.